e-Therapeutics' ETS610 misses targets, shares tank

16 February 2016

UK drug discovery firm e-Therapeutics (AIM: ETX) yesterday reported disappointing top-line results for its Phase IIb trial of ETS6103 in major depressive disorder, evaluating its antidepressant activity and tolerance profile, showing the drug was less effective than tricyclic alternatives.

The company’s plunged 38% to 16.00 pence on the news, making it one of the worst performers in the AIM All-Share early Monday, but recovered later to be down just 1.9% at 21.10 pence in early trading today.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK